CSL
CompanyAustraliaFounded 1994
CSL develops one asset. Mostly antibody acting on CLDN1; based in Australia, founded in 1994.
- 1
- Asset
- Furthest stage
- Not known
- 1
- Trial
- 1
- Signal
Pipeline
1Monoclonal antibody targeting Claudin-1
Stage not known, Antibody, CLDN1, Partner
Full company profiles: pipeline, trials, funding and people.
Subsidiaries
11 trial
In the full profile
- Evidence behind the mechanisms1
- Trials2
- Signals1
- Similar companies1